The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
Exploration of Medicine · 16.10.2025 · 6
DOI: 10.37349/emed.2025.1001365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Medicine, online erschienen am 16.10.2025. Verfasst von Carlo Acierno und 8 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology and highlights the need for a more pathophysiologically based classification. The aim of this review is to critically examine the conceptual evolution from NAFLD to MASLD, highlighting the implications for pathogenesis, diagnosis, risk stratification, and therapeutic strategies within the broader context of systemic metabolic dysfunction. Unlike the exclusion-based NAFLD definition, MASLD is grounded in positive diagnostic criteria and recognizes hepatic steatosis as a manifestation of metabolic disease. This reclassification improves clinical risk assessment and aligns hepatic care with cardiometabolic management. MASLD is closely linked to insulin resistance, lipotoxicity, chronic inflammation, and gut dysbiosis, which contribute to cardiovascular disease, chronic kidney disease, type 2 diabetes, and hepatocellular carcinoma. Non-invasive tools (e.g., FIB-4, elastography, ELF score) and emerging biomarkers (e.g., miR-122, CK-18, FGF21) support early diagnosis and personalized approaches. Therapeutically, MASLD management includes lifestyle modification, antidiabetic agents (GLP-1 receptor agonists, SGLT2 inhibitors), PPAR agonists, and novel drugs such as resmetirom. This evolving framework demands integrated, multidisciplinary strategies to address the systemic burden and clinical heterogeneity of MASLD.
Zitieren
APA
Acierno, C., Nevola, R., Barletta, F., Zielińska, K., Rinaldi, L., Sasso, F. C., Conte, C., Adinolfi, L. E., & Caturano, A. (2025). The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management. Exploration of Medicine, 6. https://doi.org/10.37349/emed.2025.1001365
Vancouver
Acierno C, Nevola R, Barletta F, Zielińska K, Rinaldi L, Sasso FC, et al. The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management. Exploration of Medicine. 2025;6. doi:10.37349/emed.2025.1001365
BibTeX
@article{Acierno2025,
author = {Acierno, Carlo and Nevola, Riccardo and Barletta, Fannia and Zielińska, Katarzyna and Rinaldi, Luca and Sasso, Ferdinando Carlo and Conte, Caterina and Adinolfi, Luigi Elio and Caturano, Alfredo},
title = {The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management},
journal = {Exploration of Medicine},
year = {2025},
volume = {6},
doi = {10.37349/emed.2025.1001365}
}
EUVIMED